▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #815 by analyst upside · 2026-11-13
CADL
Candel Therapeutics, Inc.
Healthcare · Market Cap $642M · P/E 0x
ANALYST PRICE TARGET
+163.5%
implied upside to consensus target
Current Price $8.39
Consensus Target $22.11
Bull Target $29.0
Bear Target $15.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
9
Hold
0
Sell
0
52-Week Low $4.35
52-Week High $14.0
YTD Return +54.2%
FUNDAMENTALS
Market Cap $642M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.46
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.35
52-Week High $14.0
Current Price $8.39
Bear Target $15.0
Bull Target $29.0
● Now $8.39 ● Target $22.11
TRADING DATA
Avg Volume 1.2M
YTD Return +54.2%
Analyst Count 9
Consensus Buy
Upside to Target +163.5%
Last Updated 2026-11-13

ANALYST SUMMARY

Candel Therapeutics, Inc. (CADL) is currently trading at $8.39 with a Wall Street consensus price target of $22.11, implying potential upside of 163.5% over the next 12 months. 9 analysts currently cover CADL, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $29.0, while the most cautious has a target of $15.0.

CADL operates in the Healthcare sector with a market capitalisation of $642M. The stock is up 54.2% year-to-date and is currently trading near the lower end of its 52-week range of $4.35 – $14.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CADL, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Jefferies ● Initiated
Buy 2026-10-22 50% win rate (6 calls)
B of A Securities ↑ Upgrade
Neutral → Buy 2026-09-21 Building track record
B of A Securities - Reiterated
Neutral → Neutral 2026-08-14 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-08-13 31% win rate (48 calls)
Stifel ● Initiated
Buy 2026-07-13 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2026-04-20 40% win rate (10 calls)
Citigroup - Reiterated
Buy → Buy 2026-03-18 Building track record
Citigroup - Reiterated
Buy → Buy 2026-03-13 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →